Treatment adherence improves outcomes and manages costs

Area of Science:

• Infectious Diseases
• Pharmacology
• Public Health

Background:

• Chronic disease treatment adherence averages 50%, but HIV requires 95%+ adherence for optimal outcomes.
• Highly active antiretroviral therapy (HAART) is effective and cost-effective, reducing hospitalizations and improving quality of life.
• Real-world adherence to antiretroviral treatment (ART) often falls short of clinical trial performance, necessitating adherence strategies.

Purpose of the Study:

• To highlight the critical need for high adherence in HIV treatment with HAART.
• To explore strategies for improving patient adherence to complex antiretroviral regimens.
• To evaluate the cost-effectiveness of interventions like treatment adherence committees (TACs) in managed care.

Main Methods:

• Review of existing literature on chronic disease and HIV treatment adherence.
• Analysis of cost-effectiveness data for HAART, including drug costs versus healthcare utilization savings.
• Discussion of multidisciplinary approaches to enhance patient adherence to antiretroviral therapy.

Main Results:

• HAART significantly improves outcomes and quality of life, with cost savings from reduced hospitalizations.
• High adherence (95%+) is essential for HAART efficacy and preventing antiretroviral resistance.
• Dedicated TACs show promise as effective components of adherence strategies in managed care settings.

Conclusions:

• Improving adherence to HAART is paramount for successful long-term HIV management.
• Multifaceted strategies targeting patients, providers, and treatment regimens are necessary.
• TACs represent a potentially cost-effective addition to managed care for enhancing HIV treatment adherence.